Skip to main content

Panitumumab Side Effects

Medically reviewed by Last updated on Jun 5, 2023.

Applies to panitumumab: intravenous solution.


Intravenous route (Solution)

Dermatologic toxicities were reported in 90% of patients and were severe in 15% of patients receiving panitumumab monotherapy.

Serious side effects of Panitumumab

Along with its needed effects, panitumumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking panitumumab:

More common

Less common


Incidence not known

For Healthcare Professionals

Applies to panitumumab: intravenous solution.


Very common (10% or more): Erythema (66%), pruritus (58%), acneiform dermatitis (57%), rash (22%), skin fissures (20%), exfoliative rash (18%), alopecia (15%)

Common (1% to 10%): Dry skin, nail disorder, skin exfoliation, skin ulcer, pustular rash, popular rash, Palmar-plantar erythrodysesthesia syndrome

Postmarketing reports: Skin necrosis, life threatening and fatal bullous mucocutaneous disease[Ref]


Very common (10% or more): Abdominal pain (25%), nausea (23%), diarrhea (21%), constipation (21%), vomiting (19%)

Common (1% to 10%): Stomatitis, mucosal inflammation, dry mouth[Ref]

When used in combination with irinotecan, the incidence and severity of diarrhea is increased. In a study of 19 patients who received panitumumab in combination with irinotecan, 5-fluorouracil, and leucovorin, the incidence of grade 3 or 4 diarrhea was 58% and was fatal in one patient. The combination of panitumumab with leucovorin is not recommended.[Ref]


Very common (10% or more): Anorexia (36%), hypomagnesemia (30%), hypokalemia (21%), weight loss (18%)

Common (1% to 10%): Dehydration

Frequency not reported: Hypocalcemia[Ref]

Median magnesium levels decreased by 0.1 mmol/L. Hypomagnesemia (grade 3 or 4) requiring oral or IV electrolyte repletion occurred in 2% of patients. Hypomagnesemia occurred 6 weeks or longer after the initiation of panitumumab. In some patients, hypomagnesemia was associated with hypocalcemia. Patient's electrolytes should be monitored during and for eight weeks after the completion of panitumumab therapy. Patients should be periodically monitored for hypomagnesemia and accompanying hypocalcemia during the eight weeks after the completion of panitumumab therapy.[Ref]


Very common (10% or more): Dyspnea (18%), cough (15%)

Common (1% to 10%): Epistaxis, pulmonary embolism

Uncommon (0.1% to 1%): Pulmonary fibrosis

Frequency not reported: Nasal dryness, interstitial lung disease (including fatal cases), lung infiltrates[Ref]

Panitumumab should be permanently discontinued in patients developing interstitial lung disease, pneumonitis, or lung infiltrates.[Ref]


Common (1% to 10%): Growth of eyelashes, blepharitis, increased lacrimation, ocular hyperemia, dry eye, eye pruritus, eye irritation, conjunctivitis

Uncommon (0.1% to 1%): eyelid irritation, keratitis

Rare (less than 0.1%): Ulcerative keratitis[Ref]


Severe infusion reactions were identified as anaphylactic reaction, bronchospasm, fever, chills, and hypotension. Although fatal infusion reactions have not been reported with panitumumab, fatalities have occurred with other monoclonal antibody products. The infusion should be stopped if a severe infusion reaction occurs. Depending on the severity and/or persistence of the reaction, panitumumab may need to be permanently discontinued.[Ref]

Common (1% to 10%): Hypersensitivity

Rare (less than 0.1%): Anaphylactic reaction, infusion reaction[Ref]


Very common (10% or more): Anemia

Common (1% to 10%): Leukopenia[Ref]


Very common (10% or more): Paronychia (25%)

Common (1% to 10%): Pustular rash, cellulitis, folliculitis, localized infection

Uncommon (0.1% to 1%): Eye infection, eyelid infection

Postmarketing reports: Angioedema[Ref]

Nervous system

Frequency not reported: Headache[Ref]


Very common (10% or more): Fatigue (26%), peripheral edema (12%)

Common (1% to 10%): Mucosal inflammation, pyrexia, chills[Ref]


Frequency not reported: Acute renal failure (in patients who developed diarrhea and dehydration)[Ref]


1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Pharmaceutical Society of Australia. APPGuide online. Australian prescription products guide online. 2006.

3. Product Information. Vectibix (panitumumab). Amgen USA. 2006.

4. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.